On the front of the fight against chikungunya, Valneva comes to bring the good news.

The Franco-Austrian laboratory Valneva announced Thursday “initial positive results” for its vaccine against this virus.

The serum is currently in phase III trials, the last before a marketing application.

Final results are expected within the next six months.

Tested on 4,115 adults in the United States, the vaccine generated "neutralizing antibody titers in 98.5% of participants 28 days after a single injection of the candidate vaccine," explains Valneva.

It is therefore well beyond the threshold of 70% agreed with the American regulator, the FDA, "which can be used as part of a marketing authorization application".

A "major, growing and unsatisfied public health threat"

The vaccine candidate "has also been shown to be highly immunogenic including in elderly participants", welcomes Valneva, and was "generally well tolerated".

"These first results from a phase III trial for a chikungunya vaccine mean that we have taken one more step towards addressing this major, growing and unmet public health threat," explains Juan Carlos Jaramillo, medical officer of health in chief at Valneva, quoted in the press release from the laboratory.

In addition to a vaccine against chikungunya, a virus transmitted by mosquitoes, Valneva is also developing a vaccine against Covid-19, currently in a phase III clinical study.

Its Lyme disease serum is in phase II of clinical trials on humans, the intermediate step aimed at ensuring its effectiveness.

Health

The Valneva laboratory launches a Phase III clinical study for its vaccine candidate

Health

Sanofi acquires the American Translate Bio, specialist in messenger RNA

  • Vaccine

  • Virus

  • Pharmaceutical industry

  • Health

  • Chikungunya